279 related articles for article (PubMed ID: 33962348)
1. Diabetes in Individuals With Tuberous Sclerosis Complex Treated With mTOR Inhibitors.
Agricola K; Stires G; Krueger DA; Capal JK; Franz DN; Ritter DM
Pediatr Neurol; 2021 Jul; 120():7-10. PubMed ID: 33962348
[TBL] [Abstract][Full Text] [Related]
2. Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience.
Krueger DA; Capal JK; Curatolo P; Devinsky O; Ess K; Tzadok M; Koenig MK; Narayanan V; Ramos F; Jozwiak S; de Vries P; Jansen AC; Wong M; Mowat D; Lawson J; Bruns S; Franz DN;
Eur J Paediatr Neurol; 2018 Nov; 22(6):1066-1073. PubMed ID: 30005812
[TBL] [Abstract][Full Text] [Related]
3. Management of side effects of mTOR inhibitors in tuberous sclerosis patients.
Sadowski K; Kotulska K; Jóźwiak S
Pharmacol Rep; 2016 Jun; 68(3):536-42. PubMed ID: 26891243
[TBL] [Abstract][Full Text] [Related]
4. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
6. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
7. Treatment of tuberous sclerosis complex manifestations in children with mTOR inhibitors.
Yeşil Ş; Kurucu B; Hamamcı MB; Yılmaz Ş; Şahin G
Childs Nerv Syst; 2024 Mar; 40(3):831-837. PubMed ID: 37947859
[TBL] [Abstract][Full Text] [Related]
8. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
[TBL] [Abstract][Full Text] [Related]
9. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitor Use-Long-term Follow-up of First Tuberous Sclerosis Complex Patient Treated De Novo With Sirolimus After Kidney Transplantation: A Case Report.
Tarasewicz A; Dębska-Ślizień A; Rutkowska B; Szurowska E; Matuszewski M
Transplant Proc; 2018; 50(6):1904-1909. PubMed ID: 30056926
[TBL] [Abstract][Full Text] [Related]
11. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex-A Systematic Review.
Sugalska M; Tomik A; Jóźwiak S; Werner B
Int J Environ Res Public Health; 2021 May; 18(9):. PubMed ID: 34062963
[TBL] [Abstract][Full Text] [Related]
13. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives.
Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A
CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102
[TBL] [Abstract][Full Text] [Related]
15. An updated meta-analysis of effectiveness and safety of mTOR inhibitors in the management of tuberous sclerosis complex patients.
Liu M; Ye J; You X
Childs Nerv Syst; 2024 Mar; 40(3):823-829. PubMed ID: 37906297
[TBL] [Abstract][Full Text] [Related]
16. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
17. Dramatic relapse of seizures after everolimus withdrawal.
Mingarelli A; Vignoli A; La Briola F; Peron A; Giordano L; Banderali G; Canevini MP
Eur J Paediatr Neurol; 2018 Jan; 22(1):203-206. PubMed ID: 28888335
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Everolimus Treatment in Individuals With Tuberous Sclerosis Complex: A Review of the Current Literature.
Tran LH; Zupanc ML
Pediatr Neurol; 2015 Jul; 53(1):23-30. PubMed ID: 26092412
[TBL] [Abstract][Full Text] [Related]
20. Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.
Davies M; Saxena A; Kingswood JC
Orphanet J Rare Dis; 2017 Feb; 12(1):35. PubMed ID: 28202028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
